C54.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM C54.1 became effective on October 1, 2020. This is the American ICD-10-CM version of C54.1 - other international versions of ICD-10 C54.1 may differ.
Serous tubal intraepithelial carcinoma (STIC): abnormal histology (high N:C, loss of polarity, lack of ciliated cells, strong and diffuse p53 or rarely completely negative) ICD coding ICD-10: N83.9 - fallopian tube disorder
Malignant neoplasm of specified parts of peritoneum. C48.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM C48.1 became effective on October 1, 2019. This is the American ICD-10-CM version of C48.1 - other international versions of ICD-10 C48.1 may differ.
2018/2019 ICD-10-CM Diagnosis Code C57.00. Malignant neoplasm of unspecified fallopian tube. C57.00 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Serous tubal intraepithelial carcinoma (STIC) is a rare pathologic finding at the time of benign gynecologic surgery. It arises in the distal fimbriated end of the fallopian tube and likely represents a precursor lesion to high-grade pelvic serous carcinoma.
C56. 9 - Malignant neoplasm of unspecified ovary | ICD-10-CM.
C56. 1 - Malignant neoplasm of right ovary. ICD-10-CM.
Benign neoplasm of unspecified ovaryborderline malignancy D39.1-proliferating D39.1-
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
C55 - Malignant neoplasm of uterus, part unspecified. ICD-10-CM.
A rare cancer of the uterus, ovary, or fallopian tubes.
Rule H26 Code 8541/3 (Paget disease and infiltrating duct carcinoma) for Paget disease and invasive duct carcinoma.
The International Classification of Diseases for Oncology, third edition (ICD-O-3), is designed to categorize tumors. It is used primarily in tumor or cancer registries for coding the site (topography) and the histology (morphology) of neoplasms, usually obtained from a pathology report and in research.
Borderline ovarian tumours are abnormal cells that form in the tissue covering the ovary. They are not cancer and are usually cured with surgery.
Results: The majority (78%) of ovarian borderline tumors primarily were encountered and staged by general obstetrician-gynecologists. Overall, 66% of patients had at least 1 staging biopsy performed.
A borderline tumor, sometimes called low malignant potential (LMP) tumor, is a distinct but yet heterogeneous group of tumors defined by their histopathology as atypical epithelial proliferation without stromal invasion.
Borderline ovarian tumors (BOTs) comprise 10–20% of ovarian malignancies (1). Although they are similar to malignant epithelial ovarian tumors in some of the histologic characteristics, these types of tumors do not have destructive stromal invasion (2). Their prognosis is much better than that of carcinoma (3).
A serous cystadenoma is a very common non-cancerous type of ovarian tumour. It develops from the cells on the surface of the ovary. While these tumours are non-cancerous, they can grow to be very large in size and as a result can cause significant symptoms for many patients.
The current 2014 WHO Classification of Tumours of the Female Genital Organs uses the term “borderline tumor” interchangeable with “atypical proliferative tumor”—a terminology that was discouraged in the previous WHO classification [4], whereas the previously advocated synonym “tumor of low malignant potential” is no ...
Borderline ovarian tumors, often referred to as “low malignant potential” tumors, are not invasive but also not completely benign. Their behavior can also vary based on microscopic features, and some are more likely to recur or spread than others.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C57.00 became effective on October 1, 2021.
Cite this page: Mubeen A, Gopinath A. Serous tubal intraepithelial carcinoma. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/fallopiantubesstic.html. Accessed February 21st, 2022.
Cite this page: Mubeen A, Gopinath A. Serous tubal intraepithelial carcinoma. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/fallopiantubesstic.html. Accessed February 21st, 2022.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C48.1 became effective on October 1, 2021.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C54.1 became effective on October 1, 2021.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
New abnormal tissue that grows by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease; tumors perform no useful body function and may be benign or malignant; benign neoplasms are a noncancerous growth that does not invade nearby tissue or spread to other parts of the body; malignant neoplasms or cancer show a greater degree of anaplasia and have the properties of invasion and metastasis; neoplasm terms herein do not distinguish between benign or malignant states, use references listed to cover this concept.
Sarcoma is a malignancy that begins in bone, cartilage, fat, muscle, blood vessels, or other connective or supportive tissue. Leukemia is a malignancy that starts in blood-forming tissue such as the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the blood.
The 2022 edition of ICD-10-CM C80.1 became effective on October 1, 2021.